Vertex Report Positive Results for Cystic Fibrosis Combo

Vertex have announced positive late-stage clinical trial results for their drug combo to treat cystic fibrosis (CF), taking a leap closer to regulatory filing. Vertex confirmed that the combination of lumacaftor and Kalydeco, resulted in statistically significant improvements in lung function compared to placebo, for patients aged 12 years and over with two copies of

Continue Reading

Johnson & Johnson and Vertex’s Incivo Receives EU Approval

he European Commission has approved Johnson & Johnson and Vertex Pharmaceuticals’ hepatitis C drug, Incivo (telaprevir), a direct-acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin. The approval was based on data from three Phase III studies involving 2,290 patients. Two of these studies,

Continue Reading